CN108026160A - 新型igfr-样受体及其用途 - Google Patents

新型igfr-样受体及其用途 Download PDF

Info

Publication number
CN108026160A
CN108026160A CN201680051667.1A CN201680051667A CN108026160A CN 108026160 A CN108026160 A CN 108026160A CN 201680051667 A CN201680051667 A CN 201680051667A CN 108026160 A CN108026160 A CN 108026160A
Authority
CN
China
Prior art keywords
igfr
receptor
seq
antagonist
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680051667.1A
Other languages
English (en)
Chinese (zh)
Inventor
H·利克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of CN108026160A publication Critical patent/CN108026160A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
CN201680051667.1A 2015-09-07 2016-09-07 新型igfr-样受体及其用途 Pending CN108026160A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92818 2015-09-07
LU92818 2015-09-07
PCT/EP2016/071126 WO2017042242A1 (en) 2015-09-07 2016-09-07 Novel igfr-like receptor and uses thereof

Publications (1)

Publication Number Publication Date
CN108026160A true CN108026160A (zh) 2018-05-11

Family

ID=54337321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680051667.1A Pending CN108026160A (zh) 2015-09-07 2016-09-07 新型igfr-样受体及其用途

Country Status (8)

Country Link
US (1) US20190248905A1 (https=)
EP (2) EP3896080A1 (https=)
JP (3) JP7175760B2 (https=)
CN (1) CN108026160A (https=)
DK (1) DK3347376T3 (https=)
ES (1) ES2862175T3 (https=)
PL (1) PL3347376T3 (https=)
WO (1) WO2017042242A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3096533C (en) 2018-04-27 2023-08-29 Aimed Bio Inc. Magnetic-based biopanning method through attachment of magnetic bead to cell
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
EP4373855A1 (en) 2021-07-23 2024-05-29 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Igfr-l1 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017563A1 (en) * 1997-03-31 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2007005987A2 (en) * 2005-07-06 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting maba1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20110229480A1 (en) * 2008-09-04 2011-09-22 Oxford Biotherapeutics Ltd Pta072 protein
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017563A1 (en) * 1997-03-31 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2007005987A2 (en) * 2005-07-06 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting maba1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KENNETH SIDDLE: "Signalling by insulin and IGF receptors: supporting acts and new players", 《JOURNAL OF MOLECULAR ENDOCRINOLOGY》 *
RIVE SARFSTEIN ET AL: "Minireview: Nuclear Insulin and Insulin-like Growth Factor-1 Receptors: A Novel Paradigm in Signal Transduction", 《ENDOCRINOLOGY》 *

Also Published As

Publication number Publication date
JP2023015235A (ja) 2023-01-31
ES2862175T3 (es) 2021-10-07
JP2025166096A (ja) 2025-11-05
EP3896080A1 (en) 2021-10-20
EP3347376A1 (en) 2018-07-18
JP7807359B2 (ja) 2026-01-27
US20190248905A1 (en) 2019-08-15
JP2018528213A (ja) 2018-09-27
JP7175760B2 (ja) 2022-11-21
EP3347376B1 (en) 2021-01-06
PL3347376T3 (pl) 2021-12-06
WO2017042242A1 (en) 2017-03-16
DK3347376T3 (da) 2021-03-29

Similar Documents

Publication Publication Date Title
JP7807359B2 (ja) 新規なｉｇｆｒ様レセプター及びその使用
US20140303078A1 (en) Modulation of pancreatic beta cell proliferation
US20110179502A1 (en) Modulation of gm98 (mrf) in remyelination
US7247705B2 (en) Proteins having glucose transporter activity
JP5954800B2 (ja) 男性不妊症の原因因子検出方法及び男性不妊症モデル動物
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
WO2022057903A1 (en) Genetically modified non-human animal with human or chimeric glp1r
US12583928B2 (en) Antibodies against IGFR-like receptor and uses thereof
KR101460737B1 (ko) Ｍｇ53-ｕｂｅ2ｈ 상호작용을 이용한 제2형 당뇨 치료제의 스크리닝 방법
JP2008173122A (ja) 新規蛋白質およびその用途
WO2006068326A1 (ja) 新規ポリペプチドおよびその用途
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
WO2004048565A1 (ja) アポトーシス関連蛋白質およびその用途
JP5378202B2 (ja) 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
EP1574575A1 (en) GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE
US20110104705A1 (en) Musclin receptor and use thereof
JP4761812B2 (ja) マスクリン受容体およびその用途
CN117980340A (zh) Igfr-l1抗体及其用途
Suda INTERACTION BETWEEN HEMATOPOIETIC STEM CELLS AND ENDOTHELIAL CELLS
WO2004081039A1 (ja) 新規タンパク質およびそのｄｎａ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination